Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms has to be demonstrated through meticulous preclinical testing before their introduction into the clinical setting. The gold standard in the preclinical assessment and quality control of antivenoms is the neutralization of venom-induced lethality. In addition, depending on the pathophysiological profile of snake venoms, the neutralization of other toxic activities has to be evaluated, such as hemorrhagic, myotoxic, edema-forming, dermonecrotic, in vitro coagulant, and defibrinogenating effects. There is a need to develop laboratory assays to evaluate neutralization of other relevant venom activities. The concept of the 3Rs (Replacement, Reduction, and Refinement) in Toxinology is of utmost importance, and some advances have been performed in their implementation. A significant leap forward in the study of the immunological reactivity of antivenoms against venoms has been the development of “antivenomics”, which brings the analytical power of mass spectrometry to the evaluation of antivenoms. International partnerships are required to assess the preclinical efficacy of antivenoms against snake venoms in different regions of the world in order to have a detailed knowledge on the neutralizing profile of these immunotherapeutics.
Snakebite is a Neglected Tropical Disease estimated to cause more than 100,000 human deaths and disable more than 400,000 victims each year. It primarily affects poor agricultural workers, farmers, and cattle herders living in rural areas of developing countries. It is thus an occupational disease. However, the impact of snakebite on these rural communities could be even higher if a One Health approach is taken to consider the direct impact on domestic animals and indirect impact on the livelihood of affected communities. To explore this hypothesis we developed the first scoping review to identify and characterize the global literature on snakebite in domestic animals. Three bibliographic databases (PubMed, Web of Science and Agricola) were searched using terms related to snake, snakebite and domestic animals for publications up to December 31st, 2016. Two independent reviewers screened publications applying inclusion/exclusion criteria to select relevant material. Relevant information was then extracted from the selected literature. The global literature on snakebite in domestic animals (n = 143 observational studies, reviews and letters) mainly represented North America, Europe and Australia (69%) with less information from Central and South America, Asia and Africa (31%). Observational studies (n = 119) mostly concerned pets (78%) and to a lesser extent livestock (22%). Thirty-four snake species were reported as responsible for bites in domestic animals. WHO's Medically Important Venomous Snakes were more frequently involved. The social-ecological determinants of snakebite were poorly documented but the reviewed literature suggested a strong seasonality and a diversity of habitat. Snakebite in animals caused neurotoxic, cytotoxic and hemotoxic envenomation syndromes similar to humans and death. Half of publications on envenomed livestock reported a fatality rate above 47%. There was no literature on the indirect impact of snakebite on livelihood caused by animal morbidity and mortality. The results of this scoping review suggest a high and under-reported burden in terms of mortality in animals and a potential economic impact of snakebite in terms of losses in livelihood of affected communities. However, major knowledge gaps with respect to impact of snakebite on livestock and livelihood were identified. Filling these gaps is necessary for a full understanding of the impact of snakebite and to raise scientific, political and public awareness on this neglected issue.
There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory phospholipase A2 (sPLA2) inhibitor, LY333013, demonstrates antidotal characteristics for severe snakebite envenoming in both field and hospital use. A murine model of lethal envenoming by a Papuan taipan (Oxyuranus scutellatus) demonstrates that LY333013, even with delayed oral administration, improves the chances of survival. Furthermore, LY333013 improves the performance of antivenom even after it no longer reverses neurotoxic signs. Our study is the first demonstration that neurotoxicity from presynaptic venom sPLA2S can be treated successfully, even after the window of therapeutic antivenom has closed. These results suggest that sPLA2 inhibitors have the potential to reduce death and disability and should be considered for the initial and adjunct treatment of snakebite envenoming. The scope and capacity of the sPLA2 inhibitors ability to achieve these endpoints requires further investigation and development efforts.
Snakebite envenoming is a life-threatening disease in humans and animals and a major public health issue in rural communities of South-East Asia and sub-Saharan Africa. Yet the impact of snakebite on domestic animals has been poorly studied. This study aimed to describe the context, clinical features, treatment, and outcomes of snakebite envenoming in domestic animals in Nepal and Cameroon. Primary data on snakebite in animals were recorded from a community-based nation-wide survey on human and animal snakebite in Nepal and Cameroon (Snake-byte project). Mobile teams collected data on snakebite in humans and animals in 13,879 and 10,798 households in Nepal and Cameroon respectively from December 2018 to June 2019. This study included 405 snakebite cases (73 in Nepal and 332 in Cameroon) in multiple types of animals. An interview with a structured questionnaire collected specific information about the animal victims.